Connect your AI

Castle Biosciences CSTL Debt Instrument, Fair Value Disclosure

Debt Instrument, Fair Value Disclosure at other companies

BlackstoneBX

$11.95B+6.6%

MSCIMSCI

$6.13B+44.7%

Apollo Global ManagementAPO

$13.47B+32.4%

LennarLEN

$4.11B+85.3%

KEE

Keel Infrastructure Corp. Common StockKEEL

$590.25M—

Service Corporation InternationalSCI

$78.18M-8.0%

Other financials

Income statement

Revenue$83.7M-4.9%

Gross profit$63.1M-11.8%

Operating income-$18.4M+34.1%

Net income-$14.5M+43.8%

EPS (diluted)-$0.49+45.6%

Balance sheet

Cash & equivalents$63.8M-28.9%

Total debt$36.7M+42.1%

Total equity$461.4M+4.8%

Total assets$547.8M+9.2%

Cash flow

Operating cash flow-$22.1M-267%

CapEx$12.5M+163%

Free cash flow-$34.6M-221%

Valuation

Market cap$694.86M+29.9%

Enterprise value$667.82M+41.8%

P/S2×+0.5×

Profitability

Gross margin77.9%-4.1pp

Operating margin-9.8%-30.8pp

Net margin-3.8%-10.2pp

FCF margin1.3%-10.7pp

Returns & leverage

Return on equity-2.8%-10.6pp

Debt / equity0.1×0.0×

Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFairValue.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's debt instrument, fair value disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Castle Biosciences's debt instrument, fair value disclosure?: Castle Biosciences (CSTL) reported debt instrument, fair value disclosure of $10.07M in Q1 2026.